Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 209 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2014', provides an overview of the Non-Alcoholic Steatohepatitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Non-Alcoholic Steatohepatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Non-Alcoholic Steatohepatitis Overview 8
Therapeutics Development 9
Pipeline Products for Non-Alcoholic Steatohepatitis - Overview 9
Pipeline Products for Non-Alcoholic Steatohepatitis - Comparative Analysis 10
Non-Alcoholic Steatohepatitis - Therapeutics under Development by Companies 11
Non-Alcoholic Steatohepatitis - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Non-Alcoholic Steatohepatitis - Products under Development by Companies 17
Non-Alcoholic Steatohepatitis - Companies Involved in Therapeutics Development 20
Isis Pharmaceuticals, Inc. 20
Gilead Sciences, Inc. 21
Daiichi Sankyo Company, Limited 22
Novo Nordisk A/S 23
Mochida Pharmaceutical Co., Ltd. 24
Cubist Pharmaceuticals, Inc. 25
Kissei Pharmaceutical Co., Ltd. 26
Zydus Cadila Healthcare Limited 27
Shire Plc 28
Genfit SA 29
La Jolla Pharmaceutical Company 30
ProMetic Life Sciences Inc. 31
Immuron Limited 32
Galectin Therapeutics, Inc. 33
Raptor Pharmaceuticals Corp. 34
Jenrin Discovery, Inc. 35
Phenex Pharmaceuticals AG 36
Wellstat Therapeutics Corporation 37
Zafgen Inc. 38
Conatus Pharmaceuticals Inc. 39
Cardax Pharmaceuticals, Inc. 40
Intercept Pharmaceuticals, Inc. 41
Tobira Therapeutics, Inc. 42
Kyorin Pharmaceutical Co., Ltd. 43
Verva Pharmaceuticals Limited 44
NasVax Ltd. 45
Stelic Institute & Co. 46
Dr. Falk Pharma GmbH 47
Galmed International Ltd. 48
Connexios Life Sciences Pvt. Ltd. 49
Kadmon Corporation, LLC 50
Non-Alcoholic Steatohepatitis - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Target 52
Assessment by Mechanism of Action 56
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
GFT-505 - Drug Profile 64
KD-025 - Drug Profile 67
cenicriviroc - Drug Profile 68
cysteamine DR - Drug Profile 70
saroglitazar - Drug Profile 73
obeticholic acid - Drug Profile 74
liraglutide (recombinant) - Drug Profile 77
Aramchol - Drug Profile 79
emricasan - Drug Profile 81
simtuzumab - Drug Profile 84
Anti-CD3 Oral Immunotherapy - Drug Profile 86
IMM-124E - Drug Profile 88
Px-102 - Drug Profile 90
icosapent ethyl - Drug Profile 91
norursodeoxycholic acid - Drug Profile 92
Px-104 - Drug Profile 93
MGL-3196 - Drug Profile 95
GR-MD-02 - Drug Profile 97
SHP-626 - Drug Profile 99
TGFTX-3 Program - Drug Profile 100
PN-2XXX - Drug Profile 101
methazolamide - Drug Profile 102
solithromycin - Drug Profile 103
tipelukast - Drug Profile 105
GCS-100 - Drug Profile 107
CDX-085 - Drug Profile 109
JKB-121 - Drug Profile 111
JKB-119 - Drug Profile 112
VK-0214 - Drug Profile 113
PBI-4050 - Drug Profile 114
ISIS-DGAT2Rx - Drug Profile 115
ZGN-839 - Drug Profile 116
remogliflozin etabonate - Drug Profile 117
ND-630 - Drug Profile 120
JD-5037 - Drug Profile 121
Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile 122
AM-0010 - Drug Profile 123
Px-103 - Drug Profile 124
ND-654 - Drug Profile 125
LJPC-1010 - Drug Profile 126
CNX-023 - Drug Profile 127
CNX-024 - Drug Profile 128
CNX-025 - Drug Profile 129
CNX-014 - Drug Profile 130
PZ-235 - Drug Profile 131
STNM-09 - Drug Profile 132
VVP-100-X - Drug Profile 133
Small Molecules to Inhibit ACC for Metabolic Disorders and Cancer - Drug Profile 134
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 135
Small Molecule for Non-Alcoholic Steatohepatitis - Drug Profile 136
MAT-8800 - Drug Profile 137
Non-Alcoholic Steatohepatitis - Recent Pipeline Updates 138
Non-Alcoholic Steatohepatitis - Dormant Projects 189
Non-Alcoholic Steatohepatitis - Discontinued Products 190
Non-Alcoholic Steatohepatitis - Product Development Milestones 191
Featured News & Press Releases 191
Appendix 204
Methodology 204
Coverage 204
Secondary Research 204
Primary Research 204
Expert Panel Validation 204
Contact Us 205
Disclaimer 205

List of Tables
Number of Products under Development for Non-Alcoholic Steatohepatitis, H2 2014 13
Number of Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H2 2014 14
Number of Products under Development by Companies, H2 2014 16
Number of Products under Development by Companies, H2 2014 (Contd..1) 17
Number of Products under Development by Companies, H2 2014 (Contd..2) 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Development by Companies, H2 2014 (Contd..1) 22
Products under Development by Companies, H2 2014 (Contd..2) 23
Non-Alcoholic Steatohepatitis - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 24
Non-Alcoholic Steatohepatitis - Pipeline by Gilead Sciences, Inc., H2 2014 25
Non-Alcoholic Steatohepatitis - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 26
Non-Alcoholic Steatohepatitis - Pipeline by Novo Nordisk A/S, H2 2014 27
Non-Alcoholic Steatohepatitis - Pipeline by Mochida Pharmaceutical Co., Ltd., H2 2014 28
Non-Alcoholic Steatohepatitis - Pipeline by Cubist Pharmaceuticals, Inc., H2 2014 29
Non-Alcoholic Steatohepatitis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 30
Non-Alcoholic Steatohepatitis - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 31
Non-Alcoholic Steatohepatitis - Pipeline by Shire Plc, H2 2014 32
Non-Alcoholic Steatohepatitis - Pipeline by Genfit SA, H2 2014 33
Non-Alcoholic Steatohepatitis - Pipeline by La Jolla Pharmaceutical Company, H2 2014 34
Non-Alcoholic Steatohepatitis - Pipeline by ProMetic Life Sciences Inc., H2 2014 35
Non-Alcoholic Steatohepatitis - Pipeline by Immuron Limited, H2 2014 36
Non-Alcoholic Steatohepatitis - Pipeline by Galectin Therapeutics, Inc., H2 2014 37
Non-Alcoholic Steatohepatitis - Pipeline by Raptor Pharmaceuticals Corp., H2 2014 38
Non-Alcoholic Steatohepatitis - Pipeline by Jenrin Discovery, Inc., H2 2014 39
Non-Alcoholic Steatohepatitis - Pipeline by Phenex Pharmaceuticals AG, H2 2014 40
Non-Alcoholic Steatohepatitis - Pipeline by Wellstat Therapeutics Corporation, H2 2014 41
Non-Alcoholic Steatohepatitis - Pipeline by Zafgen Inc., H2 2014 42
Non-Alcoholic Steatohepatitis - Pipeline by Conatus Pharmaceuticals Inc., H2 2014 43
Non-Alcoholic Steatohepatitis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014 44
Non-Alcoholic Steatohepatitis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2014 45
Non-Alcoholic Steatohepatitis - Pipeline by Tobira Therapeutics, Inc., H2 2014 46
Non-Alcoholic Steatohepatitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2014 47
Non-Alcoholic Steatohepatitis - Pipeline by Verva Pharmaceuticals Limited, H2 2014 48
Non-Alcoholic Steatohepatitis - Pipeline by NasVax Ltd., H2 2014 49
Non-Alcoholic Steatohepatitis - Pipeline by Stelic Institute & Co., H2 2014 50
Non-Alcoholic Steatohepatitis - Pipeline by Dr. Falk Pharma GmbH, H2 2014 51
Non-Alcoholic Steatohepatitis - Pipeline by Galmed International Ltd., H2 2014 52
Non-Alcoholic Steatohepatitis - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2014 53
Non-Alcoholic Steatohepatitis - Pipeline by Kadmon Corporation, LLC, H2 2014 54
Assessment by Monotherapy Products, H2 2014 55
Number of Products by Stage and Target, H2 2014 58
Number of Products by Stage and Mechanism of Action, H2 2014 62
Number of Products by Stage and Route of Administration, H2 2014 65
Number of Products by Stage and Molecule Type, H2 2014 67
Non-Alcoholic Steatohepatitis Therapeutics - Recent Pipeline Updates, H2 2014 142
Non-Alcoholic Steatohepatitis - Dormant Projects, H2 2014 193
Non-Alcoholic Steatohepatitis - Discontinued Products, H2 2014 194